Stem Cells used to treat heart damage
Written By Matt Schissler
Wednesday, March 21, 2012
The article link above reflects a phase three clinical trial showing how autologous cells could be used to regenerate heart tissue and muscle, thereby repairing the heart to a certain level after a heart attack. This trial is very significant to the cord blood industry. Let me lay down some background on stem cells before discussion.
As mentioned in previous posts, I’ve talked about the two different forms of stem cells:
Hematopoietic cells have been used for years to re-populate an immune system that has been taxed by radiation or chemotherapy. Simply, the radiation/chemo kills cancer, but it also kills the healthy immune system cells leaving the body weak, an unable to fight off the most mundane of diseases.
Regenerative cells are used to regenerate tissue. Think of things like skin, bone, cartilage and in this case, muscle.
Again, I will be very simple here as this is not a medical blog, but a blog that bridges medical knowledge to those interested in a simple translation.
It has historically been believed that stem cells from the cord are mostly used for hematopoietic purposes, and widely believed that the cord blood cells would have little if any regenerative therapeutic applications.
This link, if the trials are successful, show otherwise.
If autogolous cells can be used to repair muscle damage in the heart, it may open a whole new world of possibilities for cord blood stem cells. Manipulating these cells to regenerate tissue will, over time, exponentially add clinical uses for cord blood, thereby affecting the thought process of more families to store their cells.
As a good friend of mine likes to say on a daily basis: “How do you eat an elephant? One bite at a time.”
Let’s eat. We’ll be sure to follow the progress of autologous stem cells and the role they play in treating the effects of heart disease.
Special Note: This website is intended to provide information to Cord Blood America Investors and Customers. The information contained herein or any attachment contained herein does not constitute any kind of research report nor is it a recommendation to buy or sell any security mentioned herein whatsoever, and as such, it should not be construed to contain any research report analysis whatsoever. Regarding Forward-Looking Statements: Certain statements made during this presentation could be considered "forward-looking" statements within the meaning of the securities laws. These statements are subject to certain risks and uncertainties that could cause results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. CBAI disclaims any obligation to update any forward-looking statements. Some of the factors that may cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements are discussed in such public company's filings with the Securities and Exchange Commission
Statements made in this presentation, including, but not limited to, those relating to the goal of the company or subsidiaries, those relating to the private stem cell storage market's capacity grow in excess of $1 billion per year, our ability to experience growth as awareness of the industry increases, the broadened applications of stem cell therapeutics, our pricing structure remaining exclusive, the barriers to enter into the industry, the government's continued regulation of the industry, our assessment of our position in the market relative to our competitors, our projected financial performance and our anticipated future performance, are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. Such forward-looking statements involve certain risks and uncertainties, without limitation, statements regarding the company's strategic direction, prospects and future results, our ability to increase income streams and to grow revenue and earnings. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These statements are only predictions and are subject to certain risks, uncertainties and assumptions, which are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this document and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, events or circumstances after the date of such statement
Cord Blood America, Inc. ® All Rights Reserved.